Literature DB >> 26232491

Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.

D M Jiang1, S Raissouni2, J Mercer3, A Kumar2, R Goodwin4, D Y Heng2, P A Tang2, C Doll2, A MacLean5, E Powell3, J Price-Hiller6, J Monzon2, W Y Cheung7, M M Vickers8.   

Abstract

BACKGROUND: Studies of clinical outcomes of elderly patients treated with neoadjuvant chemoradiation (nCRT) for locally advanced rectal cancer (LARC) are limited. Our aim was to assess the impact of age on clinical outcomes in a large multi-institutional database. PATIENTS AND METHODS: Data for patients diagnosed with LARC who received nCRT and curative-intent surgery between 2005 and 2012 were collected from five major Canadian cancer centers. Age was analyzed as a continuous and dichotomous variable (< 70 versus ≥ 70 years) and correlated with disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS). Cox regression models were used to adjust for important prognostic factors.
RESULTS: Of 1172 patients included, 295 (25%) were ≥ 70 years, and they were less likely to receive adjuvant chemotherapy (ACT; 60% versus 79%, P < 0.0001), oxaliplatin-based ACT (12% versus 31%, P < 0.0001), less likely to complete nCT (76% versus 86%, P < 0.001), and more likely to be anemic at initiation of nCRT (42% versus 30%, P = 0.0004). In multivariate analyses, age ≥ 70 years was associated with similar DFS [hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.68-1.26, P = 0.63], similar CSS (HR 0.81, 95% CI 0.46-1.41, P = 0.45), and similar OS (HR 1.28, 95% CI 0.88-1.86, P = 0.20), compared with the younger age group. As a continuous variable, increasing age was not predictive of DFS (HR 1.00, 95% CI 0.99-1.02, P = 0.49) or CSS (HR 1.002, 95% CI 0.98-1.02, P = 0.88); however, it correlated with an inferior OS (HR 1.02, 95% CI 1.00-1.03, P = 0.04).
CONCLUSIONS: Elderly patients (≥ 70 years) who receive nCRT followed by surgery appear to have similar outcomes compared with younger patients. Decisions regarding eligibility for nCRT and surgery should not be based on age alone.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  elderly patients; neoadjuvant chemoradiation; rectal cancer; survival

Mesh:

Substances:

Year:  2015        PMID: 26232491     DOI: 10.1093/annonc/mdv331

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

Review 1.  Adjuvant treatment in older patients with rectal cancer: a population-based review.

Authors:  S L Liu; P O'Brien; Y Zhao; W M Hopman; N Lamond; R Ramjeesingh
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

Review 2.  Management of locally advanced rectal cancer in the elderly: a critical review and algorithm.

Authors:  Lara Hathout; Nell Maloney-Patel; Usha Malhotra; Shang-Jui Wang; Sita Chokhavatia; Ishita Dalal; Elizabeth Poplin; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2018-04

3.  Clinical outcomes in elderly rectal cancer patients treated with neoadjuvant chemoradiotherapy: impact of tumor regression grade : Tumor regression grade after neoadjuvant chemoradiotherapy in elderly rectal cancer patients.

Authors:  Consuelo Rosa; Monica Di Tommaso; Luciana Caravatta; Maria Taraborrelli; Lucrezia Gasparini; Fiorella Cristina Di Guglielmo; Andrea Delli Pizzi; Sebastiano Cinalli; Michele Marchioni; Marta Di Nicola; Carmine Lanci; Giampiero Ausili Cefaro; Domenico Genovesi
Journal:  J Cancer Res Clin Oncol       Date:  2020-10-07       Impact factor: 4.553

4.  Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes.

Authors:  Masoud Babaei; Lina Jansen; Yesilda Balavarca; Annika Sjövall; Amanda Bos; Tony van de Velde; Michel Moreau; Gabriel Liberale; Ana Filipa Gonçalves; Maria José Bento; Cornelia M Ulrich; Petra Schrotz-King; Valery Lemmens; Bengt Glimelius; Hermann Brenner
Journal:  Clin Colorectal Cancer       Date:  2017-09-28       Impact factor: 4.481

Review 5.  Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project.

Authors:  Mauro Podda; Patricia Sylla; Gianluca Baiocchi; Michel Adamina; Vanni Agnoletti; Ferdinando Agresta; Luca Ansaloni; Alberto Arezzo; Nicola Avenia; Walter Biffl; Antonio Biondi; Simona Bui; Fabio C Campanile; Paolo Carcoforo; Claudia Commisso; Antonio Crucitti; Nicola De'Angelis; Gian Luigi De'Angelis; Massimo De Filippo; Belinda De Simone; Salomone Di Saverio; Giorgio Ercolani; Gustavo P Fraga; Francesco Gabrielli; Federica Gaiani; Mario Guerrieri; Angelo Guttadauro; Yoram Kluger; Ari K Leppaniemi; Andrea Loffredo; Tiziana Meschi; Ernest E Moore; Monica Ortenzi; Francesco Pata; Dario Parini; Adolfo Pisanu; Gilberto Poggioli; Andrea Polistena; Alessandro Puzziello; Fabio Rondelli; Massimo Sartelli; Neil Smart; Michael E Sugrue; Patricia Tejedor; Marco Vacante; Federico Coccolini; Justin Davies; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-07-02       Impact factor: 5.469

6.  Increased Levels of Genomic Instability and Mutations in Homologous Recombination Genes in Locally Advanced Rectal Carcinomas.

Authors:  Luisa Matos do Canto; Simon J Larsen; Bruna E Catin Kupper; Maria Dirlei Ferreira de Souza Begnami; Cristóvam Scapulatempo-Neto; Annabeth Høgh Petersen; Mads M Aagaard; Jan Baumbach; Samuel Aguiar; Silvia R Rogatto
Journal:  Front Oncol       Date:  2019-05-14       Impact factor: 6.244

7.  Current Treatment Approaches and Outcomes in the Management of Rectal Cancer Above the Age of 80.

Authors:  Ali P Mourad; Marie Shella De Robles; Soni Putnis; Robert D R Winn
Journal:  Curr Oncol       Date:  2021-03-30       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.